D. Oorschot

发表

Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster

B. Yawn, B. Patterson, P. Buck, 2017 .

Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: Utilizing real‐world epidemiological data in a budget impact model

B. Patterson, K. Bruxvoort, H. Tseng, 2019 .